Glucagonoma other imaging findings
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of Glucagonoma other imaging findings |
|
Risk calculators and risk factors for Glucagonoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Other imaging studies for glucagonoma include positron emission tomography scan and somatostatin receptor scintigraphy. Scintigraphy is less sensitive than PET Scan but still useful.
Other Imaging Findings
Positron Emission Tomography
When doing this test, a small amount of a radioactive medium is injected into your body and absorbed by the organs or tissues. This radioactive substance gives off energy which in turn is used to produce the images. Positron emission tomography can provide more helpful information than either CT or MRI scans. It is useful to see if cancer has spread to the lymph nodes and it is also useful to locate where cancer has spread.
Octreoscan
Many glucagonomas express high levels of somatostatin receptors and can be imaged with a radiolabeled form of the somatostatin analog octreotide.[1]
It is less sensitive than Ga DOTATATE PET Scan with gadolinium but still useful if Ga DOTATATE is not available.
-
![Somatostatin receptor scintigraphy with SPECT acquisition. Area of increased uptake anterior to the left kidney and medial to the spleen, consistent with the pancreatic mass[2]](/images/3/3c/Scintigraphy.jpg)
Somatostatin receptor scintigraphy with SPECT acquisition. Area of increased uptake anterior to the left kidney and medial to the spleen, consistent with the pancreatic mass[2]
![Somatostatin receptor scintigraphy with SPECT acquisition. Area of increased uptake anterior to the left kidney and medial to the spleen, consistent with the pancreatic mass[2]](/index.php/File:Scintigraphy.jpg)
References
- ↑ Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L; et al. (2002). "Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis". Virchows Arch. 440 (5): 461–75. doi:10.1007/s00428-002-0609-x. PMID 12021920.
- ↑ Erdas E, Aste N, Pilloni L, Nicolosi A, Licheri S, Cappai A; et al. (2012). "Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association?". BMC Cancer. 12: 614. doi:10.1186/1471-2407-12-614. PMC 3543729. PMID 23259638.